Document is current

Article History

Received: 2 September 2022

Accepted: 10 November 2022

First Online: 22 December 2022

Declarations

:

: D.J. Bauer received travel support from AbbVie and Gilead, and speaker fees from AbbVie. D. Chromy served as a speaker and/or consultant and/or advisory board member for AbbVie, Gilead, and MSD, and received travel support from AbbVie, MSD, ViiV Healthcare, and Gilead. B. Simbrunner received travel support from AbbVie and Gilead. M. Mandorfer served as a speaker and/or consultant and/or advisory board member for AbbVie, Bristol-Myers Squibb, Collective Acumen, Gilead, and W. L. Gore & Associates and received travel support from AbbVie, Bristol-Myers Squibb, and Gilead. M. Trauner received speaker fees from BMS, Falk, Gilead, Intercept, and MSD; advisory board fees from Albireo, BiomX, Boehringer Ingelheim, Falk, Genfit, Gilead, Intercept, MSD, Novartis, Phenex, Regulus, and Shire. He also received travel grants from AbbVie, Falk, Gilead, Intercept, and Jansen and unrestricted research, grants from Albireo, Cymabay, Falk, Gilead, Intercept, MSD, and Takeda. T. Reiberger received grant support from AbbVie, Boehringer-Ingelheim, Gilead, MSD, Philips Healthcare, Gore; speaking honoraria from AbbVie, Gilead, Gore, Intercept, Roche, MSD; consulting/advisory board fee from AbbVie, Bayer, Boehringer-Ingelheim, Gilead, Intercept, MSD, Siemens; and travel support from Boehringer-Ingelheim, Gilead, and Roche. S. Aberle, A. Farthofer, R. Schmidt, R. Strassl, F. Mayer and H. Holzmann declare that they have no competing interests.

: This study was approved by the Ethics Committee of the Medical University of Vienna (No. 1968/2018) and was conducted in accordance with the Declaration of Helsinki and its amendments up to and including the 2013 amendment and the guidelines for good scientific practice of the Medical University of Vienna.